| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:AZ084
CAS:929300-19-6
Purity:>=97% Remarks:Reach out to us for more information about custom solutions.
|
AZ084 manufacturers
- AZ084
-
- $64.00 / 1mg
-
2026-02-25
- CAS:929300-19-6
- Min. Order:
- Purity: 98.34%
- Supply Ability: 10g
- AZ084
-
- $64.00 / 1mg
-
2026-02-25
- CAS:929300-19-6
- Min. Order:
- Purity: 98.34%
- Supply Ability: 10g
|
| Product Name: | AZ084 | | Synonyms: | AZ084;Methanone, (5-amino-2-pyridinyl)[9-[(2,3-dihydro-2,2-dimethyl-4-benzofuranyl)methyl]-3,9-diazaspiro[5.5]undec-3-yl]-;inhibit,CC chemokine receptor,AZ-084,Tregs differentiation,AZ084,T cells,Inhibitor,asthma,CCR,PMN,AZ 084,tumor metastasis;(5-Aminopyridin-2-yl)(9-((2,2-dimethyl-2,3-dihydrobenzofuran-4-yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)methanone;(5-Aminopyridin-2-yl)(9-((2,2-dimethyl-2,3-dihydrobenzofuran-4-yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)methanone , AZ084;AZ084, 10 mM in DMSO | | CAS: | 929300-19-6 | | MF: | C26H34N4O2 | | MW: | 434.57 | | EINECS: | | | Product Categories: | | | Mol File: | 929300-19-6.mol |  |
| | AZ084 Chemical Properties |
| Boiling point | 636.0±55.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (575.28 mM; Need ultrasonic) | | form | Solid | | pka | 9.20±0.20(Predicted) | | color | Light yellow to yellow |
| | AZ084 Usage And Synthesis |
| Uses | AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma[1]. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer[1][2]. | | in vivo | AZ084 (5 mg/kg; i.p.; every third day for 9 or 21 days) restrains the formation of the immunologically tolerant PMN and tumor cells metastasis in lung by downregulating Treg differentiation[1].
AZ084 (434.57-869.14 mg/kg; i.v.; single) shows a bioavailability >70% in rats[2]. | Animal Model: | C57BL/6 J mice (subcutaneous LLC tumor model)[1]. | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection, every third day for 9 or 21 days. | | Result: | Inhibited Treg differentiation and tumor cell colonization of the lungs and reduced the number of CD4+Foxp3+ Tregs in the lungs of LLC-exo pre-injected mice (every third day for 9 days).
Inhibited the LLC-exo-induced LLC cell seeding in lung and also significantly reduced Treg accumulation in LLC-exo stimulated mouse lungs(every third day for 21 days).
|
| Animal Model: | Female Balb/C mice, male Wistar rats and female Beagle dogs[2]. | | Dosage: | 434.57-869.14 mg/kg (in 0.9% NaCl) | | Administration: | Intravenous injection, single. | | Result: | 1.19Pharmacokinetic Parameters of AZ084 in Female Balb/C mice, male Wistar rats and female Beagle dogs[2].
| IV (434.57-869.14 mg/kg) | | Dog plasma protein binding (% free) | 45.7 | | Mu plasma protein binding (% free) | 55.6 | | Hu plasma protein binding (% free) | 31.0 | | Rat plasma protein binding (% free) | 47.0 | | Rat HW plasma PK CL (mL/min/kg) | 15.0 | | Rat HW plasma PK Vss (L/kg) | 6.0 | | Rat HW plasma PK T1/2 (h) | 5.4 | | Rat HW plasma PK Cmax (μM) | 0.5 | | Rat HW plasma PK bioavailability (%) | 68.0 |
|
| | IC 50 | CCR8: 0.9 nM (Ki) | | References | [1] Wang M, et al. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions. Cancer Immunol Immunother. 2022 Apr 15. DOI:10.1007/s00262-022-03196-3
[2] Connolly S, et al. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration. Biochem Pharmacol. 2012 Mar 15;83(6):778-87. DOI:10.1016/j.bcp.2011.12.021 |
| | AZ084 Preparation Products And Raw materials |
|